Overview

A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10+Chemotherapy in Patients With Extensive Small Cell Lung Cancer

Status:
Not yet recruiting

Trial end date:
2024-05-29

Target enrollment:

Participant gender:

Summary

This study is conducted in patients with advanced metastatic small cell lung cancer (SCLC). This study includes a single arm: the patients will receive HLX07 combination therapy with HLX10 and chemotherapy (carboplatin+etoposide) as first-line treatment. All of eligible patients will receive study drug treatment until loss of clinical benefit, unacceptable toxicity, death, withdrawal of informed consent (whichever occurs first, HLX10 treatment up to 2 years).

Phase:

Phase 2

Details

Lead Sponsor:

Shanghai Henlius Biotech

Treatments:

Carboplatin
Etoposide